Scroll

sodium aurothiomalate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4706	12244-57-4

Description:

Molecule	Description
Synonyms: sodium aurothiomalate aurolate aurothiomalate sodium gold sodium thiomalate sodium aurithiomalate myochrysine	A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis. Molecular weight: 390.07 Formula: C4H3AuNa2O4S CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 80.26 ALOGS: ROTB: None

Molecule

Description

Synonyms:

sodium aurothiomalate
aurolate
aurothiomalate sodium
gold sodium thiomalate
sodium aurithiomalate
myochrysine

A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.

Molecular weight: 390.07
Formula: C4H3AuNa2O4S
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 80.26
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.40	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	70 %	Benet LZ, Broccatelli F, Oprea TI

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1992	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	607.53	60.74	633	33229	198410	63256750
Blood parathyroid hormone decreased	582.75	60.74	213	33649	9578	63445582
Granuloma skin	563.92	60.74	200	33662	8237	63446923
Panniculitis	551.47	60.74	213	33649	11172	63443988
Rheumatoid nodule	511.80	60.74	227	33635	16928	63438232
Drug hypersensitivity	484.41	60.74	704	33158	309983	63145177
Skin necrosis	459.69	60.74	198	33664	13752	63441408
Red blood cell sedimentation rate increased	453.70	60.74	286	33576	43696	63411464
Contraindicated product administered	424.47	60.74	550	33312	217098	63238062
C-reactive protein increased	414.81	60.74	368	33494	94339	63360821
Basal cell carcinoma	368.66	60.74	213	33649	27778	63427382
Drug eruption	363.75	60.74	213	33649	28481	63426679
Hypercalcaemia	361.04	60.74	211	33651	28111	63427049
Inflammation	358.81	60.74	319	33543	81954	63373206
Ulcer	352.73	60.74	202	33660	25905	63429255
Drug intolerance	339.49	60.74	597	33265	308064	63147096
Rheumatoid arthritis	325.56	60.74	526	33336	253293	63201867
Joint swelling	316.32	60.74	599	33263	327067	63128093
Loss of personal independence in daily activities	313.27	60.74	319	33543	96971	63358189
Therapeutic product effect incomplete	301.44	60.74	352	33510	124704	63330456
Skin ulcer	300.72	60.74	220	33642	42825	63412335
Therapeutic response decreased	299.34	60.74	254	33608	61271	63393889
Drug tolerance decreased	296.04	60.74	157	33705	17316	63437844
Musculoskeletal disorder	279.55	60.74	160	33702	20484	63434676
Drug ineffective	276.95	60.74	1191	32671	1043574	62411586
Adverse reaction	275.57	60.74	126	33736	10077	63445083
Therapeutic product effect decreased	270.47	60.74	417	33445	192770	63262390
C-reactive protein abnormal	265.54	60.74	210	33652	45886	63409274
Rash pruritic	252.92	60.74	228	33634	59571	63395589
Gastric disorder	249.77	60.74	186	33676	37183	63417977
Sleep disorder	245.46	60.74	258	33604	81308	63373852
Deafness transitory	229.26	60.74	71	33791	1899	63453261
Soft tissue disorder	222.15	60.74	85	33777	4337	63450823
Synovitis	218.64	60.74	372	33490	186546	63268614
Dyspnoea	218.55	60.74	44	33818	661269	62793891
Peripheral swelling	217.47	60.74	454	33408	265488	63189672
Psoriatic arthropathy	201.26	60.74	246	33616	91274	63363886
Tenosynovitis	197.75	60.74	111	33751	13684	63441476
Musculoskeletal stiffness	192.01	60.74	349	33513	184269	63270891
Presbyacusis	187.90	60.74	67	33795	2798	63452362
Death	184.66	60.74	3	33859	374378	63080782
Pyrexia	181.13	60.74	20	33842	470458	62984702
Pleural thickening	179.97	60.74	65	33797	2818	63452342
Pleural fibrosis	178.94	60.74	68	33794	3404	63451756
Blood magnesium increased	176.64	60.74	65	33797	2973	63452187
Functional gastrointestinal disorder	175.74	60.74	71	33791	4188	63450972
Demyelination	169.87	60.74	80	33782	6840	63448320
Gastrointestinal pain	166.00	60.74	88	33774	9688	63445472
Red blood cell sedimentation rate	160.17	60.74	69	33793	4785	63450375
Arthropathy	158.06	60.74	371	33491	234421	63220739
Deafness neurosensory	156.88	60.74	68	33794	4787	63450373
Alanine aminotransferase increased	154.86	60.74	231	33631	103539	63351621
Aspartate aminotransferase increased	153.77	60.74	214	33648	90063	63365097
Enthesopathy	147.56	60.74	78	33784	8536	63446624
Condition aggravated	146.61	60.74	509	33353	401708	63053452
Impaired gastric emptying	142.31	60.74	81	33781	10251	63444909
Epigastric discomfort	135.20	60.74	68	33794	6712	63448448
Pneumonia viral	133.63	60.74	71	33791	7851	63447309
Tongue disorder	132.57	60.74	78	33784	10502	63444658
Hypotension	127.32	60.74	4	33858	272600	63182560
Hypersensitivity	125.86	60.74	392	33470	292293	63162867
Arthritis	124.00	60.74	222	33640	115699	63339461
Adverse event	123.86	60.74	166	33696	67393	63387767
Drug tolerance	122.09	60.74	64	33798	6885	63448275
Abnormal loss of weight	118.26	60.74	59	33803	5723	63449437
Osteoarthritis	111.58	60.74	190	33672	95153	63360007
Ankylosing spondylitis	107.59	60.74	68	33794	10406	63444754
Feeding disorder	106.37	60.74	74	33788	13288	63441872
Blood iron abnormal	105.06	60.74	48	33814	3828	63451332
Constipation	102.57	60.74	4	33858	224939	63230221
Rheumatoid lung	102.25	60.74	47	33815	3801	63451359
Rheumatic disorder	99.16	60.74	43	33819	3029	63452131
Urinary tract infection	97.41	60.74	13	33849	264671	63190489
Product use issue	96.21	60.74	297	33565	220223	63234937
Deformity	96.05	60.74	66	33796	11618	63443542
Cyst	95.99	60.74	71	33791	14028	63441132
Mobility decreased	95.43	60.74	204	33658	120955	63334205
Infection	89.37	60.74	297	33565	228876	63226284
Tendonitis	89.23	60.74	78	33784	19537	63435623
Asthenia	85.92	60.74	49	33813	383555	63071605
Investigation abnormal	85.48	60.74	34	33828	1924	63453236
Breast cancer	82.77	60.74	115	33747	48268	63406892
Pharyngitis	81.55	60.74	75	33787	20068	63435092
Sciatica	81.48	60.74	96	33766	34228	63420932
Oedema peripheral	78.27	60.74	6	33856	189505	63265655
Back pain	74.61	60.74	24	33838	264121	63191039
Bone cyst	74.23	60.74	32	33830	2222	63452938
Finger deformity	73.89	60.74	48	33814	7697	63447463
Renal impairment	73.29	60.74	152	33710	88203	63366957
Chest pain	71.83	60.74	14	33848	215945	63239215
Intestinal sepsis	71.19	60.74	19	33843	293	63454867
Osteopenia	71.17	60.74	69	33793	19716	63435444
Blood potassium increased	68.02	60.74	65	33797	18244	63436916
Fall	63.99	60.74	69	33793	392265	63062895
Adverse drug reaction	62.47	60.74	134	33728	79580	63375580
Shoulder arthroplasty	62.27	60.74	34	33828	3968	63451192
Toxicity to various agents	62.21	60.74	27	33835	247223	63207937
Skin lesion	61.72	60.74	79	33783	30642	63424518

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Joint swelling	527.17	132.70	252	6874	59638	34890167
Red blood cell sedimentation rate increased	511.31	132.70	150	6976	9012	34940793
Apparent death	471.58	132.70	116	7010	3528	34946277
Arthropathy	431.54	132.70	173	6953	26734	34923071
Pulmonary thrombosis	394.42	132.70	117	7009	7290	34942515
Contraindicated product administered	375.32	132.70	147	6979	21334	34928471
C-reactive protein abnormal	330.01	132.70	106	7020	8604	34941201
Terminal state	298.72	132.70	82	7044	3852	34945953
Diverticulitis	297.67	132.70	122	7004	19882	34929923
Drug ineffective	296.61	132.70	409	6717	456342	34493463
C-reactive protein increased	277.87	132.70	159	6967	53939	34895866
Drug intolerance	220.52	132.70	142	6984	59428	34890377
Rheumatoid factor negative	197.48	132.70	44	7082	855	34948950
Thrombosis	188.42	132.70	121	7005	50337	34899468
Treatment failure	186.87	132.70	117	7009	46580	34903225
Photosensitivity reaction	186.51	132.70	73	7053	10521	34939284
Hand deformity	181.51	132.70	55	7071	3670	34946135
Red blood cell sedimentation rate abnormal	179.21	132.70	54	7072	3535	34946270
Bone erosion	173.24	132.70	54	7072	3961	34945844
Intestinal sepsis	164.85	132.70	36	7090	635	34949170
Drug hypersensitivity	162.63	132.70	133	6993	80396	34869409
Deep vein thrombosis	160.28	132.70	121	7005	65127	34884678
Therapeutic product effect decreased	146.37	132.70	90	7036	34653	34915152
Drug tolerance decreased	144.62	132.70	40	7086	1927	34947878
Musculoskeletal discomfort	136.38	132.70	54	7072	8014	34941791
Limb discomfort	136.16	132.70	59	7067	10988	34938817
Joint arthroplasty	133.74	132.70	32	7094	859	34948946

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	850.63	75.59	659	34567	169827	79539335
Contraindicated product administered	770.54	75.59	602	34624	156936	79552226
Red blood cell sedimentation rate increased	737.88	75.59	374	34852	45568	79663594
Drug hypersensitivity	655.41	75.59	730	34496	298186	79410976
Joint swelling	613.96	75.59	694	34532	287952	79421210
Drug intolerance	561.38	75.59	635	34591	263484	79445678
Blood parathyroid hormone decreased	561.08	75.59	201	35025	10335	79698827
Granuloma skin	545.61	75.59	190	35036	8984	79700178
C-reactive protein increased	545.26	75.59	453	34773	128574	79580588
Panniculitis	533.23	75.59	202	35024	12169	79696993
Rheumatoid nodule	519.08	75.59	218	35008	17220	79691942
C-reactive protein abnormal	491.36	75.59	291	34935	48076	79661086
Drug ineffective	469.02	75.59	1280	33946	1079633	78629529
Drug tolerance decreased	450.03	75.59	181	35045	12797	79696365
Arthropathy	429.87	75.59	457	34769	176654	79532508
Therapeutic product effect decreased	421.18	75.59	436	34790	163427	79545735
Skin necrosis	414.21	75.59	188	35038	17899	79691263
Apparent death	414.07	75.59	117	35109	2748	79706414
Rheumatoid arthritis	375.54	75.59	461	34765	208009	79501153
Loss of personal independence in daily activities	365.71	75.59	327	34899	102253	79606909
Skin ulcer	347.29	75.59	244	34982	53906	79655256
Ulcer	335.16	75.59	192	35034	29780	79679382
Basal cell carcinoma	318.36	75.59	201	35025	37174	79671988
Inflammation	314.76	75.59	289	34937	93464	79615698
Hypercalcaemia	310.76	75.59	200	35026	38230	79670932
Synovitis	298.54	75.59	350	34876	150384	79558778
Therapeutic response decreased	293.01	75.59	240	34986	66613	79642549
Drug eruption	288.74	75.59	201	35025	43734	79665428
Gastric disorder	288.41	75.59	189	35037	37244	79671918
Therapeutic product effect incomplete	274.00	75.59	325	34901	141320	79567842
Sleep disorder	269.99	75.59	255	34971	85422	79623740
Terminal state	259.20	75.59	93	35133	4796	79704366
Adverse reaction	255.73	75.59	110	35116	9204	79699958
Pulmonary thrombosis	255.12	75.59	119	35107	12052	79697110
Musculoskeletal disorder	252.15	75.59	142	35084	21306	79687856
Psoriatic arthropathy	243.54	75.59	231	34995	77768	79631394
Peripheral swelling	237.37	75.59	426	34800	269191	79439971
Dyspnoea	233.01	75.59	48	35178	856977	78852185
Rash pruritic	232.95	75.59	217	35009	71412	79637750
Musculoskeletal stiffness	228.61	75.59	331	34895	174677	79534485
Pyrexia	224.09	75.59	21	35205	678688	79030474
Hypersensitivity	212.69	75.59	400	34826	261839	79447323
Presbyacusis	189.09	75.59	63	35163	2597	79706565
Intestinal sepsis	187.38	75.59	49	35177	850	79708312
Death	185.64	75.59	18	35208	566496	79142666
Tenosynovitis	182.87	75.59	103	35123	15451	79693711
Diverticulitis	174.62	75.59	152	35074	45784	79663378
Arthritis	171.83	75.59	232	34994	114648	79594514
Pleural thickening	170.49	75.59	60	35166	2922	79706240
Hypotension	168.14	75.59	6	35220	440311	79268851
Pleural fibrosis	161.47	75.59	63	35163	4104	79705058
Blood magnesium increased	161.01	75.59	60	35166	3446	79705716
Demyelination	160.59	75.59	76	35150	7947	79701215
Deafness transitory	159.14	75.59	44	35182	951	79708211
Red blood cell sedimentation rate	156.97	75.59	67	35159	5498	79703664
Drug tolerance	148.99	75.59	74	35152	8601	79700561
Adverse event	148.58	75.59	157	35069	60057	79649105
Bone erosion	146.97	75.59	94	35132	17753	79691409
Impaired gastric emptying	145.06	75.59	77	35149	10276	79698886
Deformity	144.73	75.59	75	35151	9530	79699632
Mobility decreased	140.70	75.59	218	35008	121957	79587205
Condition aggravated	139.89	75.59	512	34714	500612	79208550
Rheumatoid lung	139.54	75.59	57	35169	4188	79704974
Osteoarthritis	136.15	75.59	180	35046	87129	79622033
Soft tissue disorder	132.17	75.59	52	35174	3463	79705699
Deafness neurosensory	130.92	75.59	63	35163	6835	79702327
Enthesopathy	128.73	75.59	74	35152	11534	79697628
Product use issue	124.98	75.59	282	34944	209540	79499622
Epigastric discomfort	122.85	75.59	63	35163	7833	79701329
Toxicity to various agents	121.98	75.59	20	35206	421520	79287642
Tongue disorder	118.54	75.59	75	35151	13900	79695262
Rheumatoid factor negative	108.79	75.59	34	35192	1139	79708023
Constipation	107.47	75.59	4	35222	283046	79426116
Urinary tract infection	107.36	75.59	3	35223	274509	79434653
Pneumonia viral	103.21	75.59	59	35167	9099	79700063
Asthenia	101.04	75.59	50	35176	511639	79197523
Aspartate aminotransferase increased	100.60	75.59	202	35024	138439	79570723
Arthralgia	100.48	75.59	508	34718	571295	79137867
Neutropenia	100.00	75.59	7	35219	287703	79421459
Ankylosing spondylitis	99.78	75.59	64	35162	12141	79697021
Blood iron abnormal	99.65	75.59	33	35193	1334	79707828
Gastrointestinal pain	99.19	75.59	59	35167	9796	79699366
Alanine aminotransferase increased	97.31	75.59	219	35007	162351	79546811
Cyst	97.19	75.59	66	35160	13774	79695388
Infection	96.18	75.59	279	34947	241433	79467729
Functional gastrointestinal disorder	92.96	75.59	45	35181	4945	79704217
Oedema peripheral	88.07	75.59	6	35220	252282	79456880
Herpes zoster	88.02	75.59	152	35074	92931	79616231
Tendonitis	84.83	75.59	76	35150	23754	79685408
Infusion related reaction	84.22	75.59	258	34968	229979	79479183
Anxiety	83.66	75.59	7	35219	248505	79460657
Chest pain	80.26	75.59	14	35212	282290	79426872
Cough	76.75	75.59	33	35193	366756	79342406
Osteopenia	76.35	75.59	64	35162	18300	79690862
Investigation abnormal	75.70	75.59	30	35196	2036	79707126

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01CB01	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS SPECIFIC ANTIRHEUMATIC AGENTS Gold preparations
CHEBI has role	CHEBI:35842	anti-rheumatic drugs
MeSH PA	D018501	Antirheumatic Agents
CHEBI has role	CHEBI:37670	protease inhibitors
CHEBI has role	CHEBI:50904	alergeno
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:131699	EC 2.7.7.7 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Juvenile rheumatoid arthritis	indication	410795001
Psoriasis with arthropathy	off-label use	33339001
Felty's syndrome	off-label use	57160007	DOID:11042

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN	Ki	6.07	DRUG MATRIX
Thioredoxin reductase 1, cytoplasmic	Enzyme	Q16881	TRXR1_HUMAN			WOMBAT-PK
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	IC50	5.62	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN	IC50	6.09	DRUG MATRIX
Cathepsin L1	Enzyme	P07711	CATL1_HUMAN	IC50	4.05	CHEMBL

External reference:

ID	Source
D00992	KEGG_DRUG
4017995	VUID
N0000146340	NUI
4017995	VANDF
CHEBI:35864	CHEBI
CHEMBL306043	ChEMBL_ID
DB09276	DRUGBANK_ID
203004	RXNORM
2006	MMSL
4795	MMSL
615	MMSL
620	MMSL
d00250	MMSL
002396	NDDF
387380005	SNOMEDCT_US
68702006	SNOMEDCT_US
C0018034	UMLSCUI
D006052	MESH_DESCRIPTOR_UI
22318	PUBCHEM_CID
4154	INN_ID
E4768ZY6GM	UNII

Pharmaceutical products:

None